Cover Image

Real‐world treatment outcomes of immune checkpoint inhibitors used off‐label in oncology: A comprehensive cancer institution experience

Abstract Off‐label use (OLU) is quite common in oncology due to the complexity of cancer and the time‐consuming regulatory process. However, outcomes of OLU in cancer treatment remain unclear. This study aimed to evaluate the overall survival (OS), event‐free survival (EFS), duration of treatment (D...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sandra Fontanals (Author), Anna Esteve (Author), Andrea González (Author), Cristina Ibáñez (Author), Ricard Mesía (Author), Ana Clopés (Author)
Format:	Book
Published:	Wiley, 2024-02-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Off-label use of oncology drugs: national survey results
by: Eva González-Haba Peña, et al.
Published: (2015)

The Glycosylation of Immune Checkpoints and Their Applications in Oncology
by: Linlin Zheng, et al.
Published: (2022)

Delayed immune-related adverse events profile associated with immune checkpoint inhibitors: a real-world analysis
by: Yana Yang, et al.
Published: (2024)

Immune Checkpoint Inhibitor-Associated Tumor Lysis Syndrome: A Real-World Pharmacovigilance Study
by: Li Wang, et al.
Published: (2021)

Hematologic and lymphatic system toxicities associated with immune checkpoint inhibitors: a real-world study
by: Na Li, et al.
Published: (2023)

Single Institution Experience with Immune Checkpoint Inhibitors in Vulvar and Vaginal Melanomas
by: Amrita Ladwa, et al.
Published: (2024)

Intrinsic Differences in Immune Checkpoint Inhibitor-Induced Myocarditis: A Retrospective Analysis of Real World Data
by: Yanna Lei, et al.
Published: (2022)

The use of biologic medications for the treatment of cutaneous immune-related adverse events secondary to immune checkpoint inhibitors: A single-institution real-life study
by: Jade N. Young, BS, et al.
Published: (2024)

Efficacy and safety of immune checkpoint inhibitors in advanced pancreatic cancer: A real world study in Chinese cohort
by: Xiaoling Gong, et al.
Published: (2022)

Immune Checkpoint Inhibitors New Insights and Recent Progress
Published: (2023)

The gut microbiota and immune checkpoint inhibitors
by: Audrey Humphries, et al.
Published: (2018)

Cardiovascular complications of immune checkpoint inhibitors
by: A. A. Kulievа, et al.
Published: (2020)

Immune Checkpoint Inhibitors and Lupus Erythematosus
by: Hans Vitzthum von Eckstaedt, et al.
Published: (2024)

Clinical observation of immune checkpoint inhibitors in the treatment of advanced pancreatic cancer: a real-world study in Chinese cohort
by: Sun D, et al.
Published: (2018)

Patient-reported outcome instruments used in immune-checkpoint inhibitor clinical trials in oncology: a systematic review
by: Sara Colomer-Lahiguera, et al.
Published: (2020)

Real-world experience of cabozantinib in Asian patients with advanced renal cell carcinoma following treatment with VEGFR tyrosine kinase inhibitors and/or immune checkpoint inhibitors
by: Darren MC Poon, et al.
Published: (2023)

Skin Manifestation Induced by Immune Checkpoint Inhibitors
by: Yamamoto T
Published: (2022)

Immune Checkpoint Inhibitors in Melanoma: Review and Update
by: Eugénia Matos Pires, et al.
Published: (2018)

Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma
by: Xi Chen, et al.
Published: (2022)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
by: Katarina Hradska, et al.
Published: (2021)

Clinical Insights Into Novel Immune Checkpoint Inhibitors
by: Jii Bum Lee, et al.
Published: (2021)

Resistance to immune checkpoint inhibitors in gastric cancer
by: Kai Liu, et al.
Published: (2023)

An overview of immune checkpoint inhibitors in breast cancer
by: Federica Miglietta, et al.
Published: (2020)

Advances in immune checkpoint inhibitors for hepatocellular carcinoma
by: Ji Won Han, et al.
Published: (2021)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview
by: Diederick J. van Doorn, et al.
Published: (2020)

Hepatobiliary complications of immune checkpoint inhibitors in cancer
by: Donna Zhuang, et al.
Published: (2024)

Immune checkpoint inhibitor-associated sarcoidosis reaction
by: Parisa Keshtgar, et al.
Published: (2023)

Mechanistic basis for Cancer Immune Evasion and role of immune checkpoint blockades in Immuno-Oncology
by: Benjamin A Babalola, et al.
Published: (2021)

Predictors of response to immune checkpoint inhibition in a real world gynecologic cancer population
by: Michelle L. Kuznicki, et al.
Published: (2020)

Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis
by: Shuo Zhang, et al.
Published: (2021)

Association of immune-checkpoint inhibitors and the risk of immune-related colitis among elderly patients with advanced melanoma: real-world evidence from the SEER-Medicare database
by: Abdulaali R. Almutairi, et al.
Published: (2021)

Immune checkpoint inhibitor‐mediated psoriasis treated with biologics
by: Pei Ming Yeo, et al.
Published: (2023)

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
by: Rilan Bai, et al.
Published: (2020)

Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma
by: Giulio Metro, et al.
Published: (2021)

Mechanisms of immune checkpoint inhibitor-mediated liver injury
by: Layla Shojaie, et al.
Published: (2021)

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
by: Pan Shen, et al.
Published: (2021)

Efficacy of immune checkpoint inhibitors in different types of melanoma
by: Ernesto Rossi, et al.
Published: (2021)

Drug therapy for myocarditis induced by immune checkpoint inhibitors
by: Yihao Wu, et al.
Published: (2023)

Acute Kidney Injury Induced by Immune Checkpoint Inhibitors
by: Ruixue Tian, et al.
Published: (2022)

Immune checkpoint inhibitor-induced acute tubulointerstitial nephritis
by: Hui Zhuan Tan, et al.
Published: (2022)